Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study
Oral semaglutide treatment for T2DM in patients with MASLD leads to an improvement in liver steatosis and injury, surrogate markers of fibrosis, diabetic status, and lipid profile, and reduces body weight.
Authors
- Joji Tani (ORCID: https://orcid.org/0000-0001-8801-2505)
- Masato Iwabu
- Tsunekazu Oikawa
- Tomomi Okubo (ORCID: https://orcid.org/0000-0003-1244-4736)
- Katsuhiko Iwakiri (ORCID: https://orcid.org/0000-0002-5558-6104)
- Toshifumi Tada (ORCID: https://orcid.org/0000-0002-0976-6761)
- Toru Ishikawa (ORCID: https://orcid.org/0000-0002-5470-9694)
- Masanori Atsukawa (ORCID: https://orcid.org/0000-0003-3374-7111)
- Mototsugu Nagao (ORCID: https://orcid.org/0000-0001-6880-5161)
- Asahiro Morishita (ORCID: https://orcid.org/0000-0002-0760-3045)
- Akihito Tsubota (ORCID: https://orcid.org/0000-0001-6860-0326)
- Keizo Kato (ORCID: https://orcid.org/0000-0003-2184-6016)
- Hiroshi Abe (ORCID: https://orcid.org/0000-0003-1106-9524)
- Taeang Arai
- Kentaro Matsuura
Institutions
- Jikei University School of Medicine (JP)
- Kagawa University (JP)
- Nagoya City University (JP)
- Saiseikai Niigata Daini Hospital (JP)
- Himeji Red Cross Hospital (JP)
- Shinmatsudo Central General Hospital (JP)
- Chiba Hokusou Hospital (JP)
- Nippon Medical School (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/dom.15898
- Citations
- 19
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.35